ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΌΠΈΡΠ΅Π½ΡΠΌΠΈ
ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ Π½Π°Π±ΠΎΡΠ° 86 ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠ² ΠΊΠΈΠ½Π°Π· ΠΈ ΠΈΡ 42 ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΠΊΠΈΠ½Π³Π° Π΄Π°Π»ΠΎ ΠΎΠ±ΡΡΡ ΡΠΎΡΠ½ΠΎΡΡΡ 77% Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΡ ΠΏΠ°Ρ ΡΠ΅ΡΠΌΠ΅Π½Ρ-ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡ. ΠΠ°ΡΡΠΎΡΡΠ°Ρ ΡΠ°Π±ΠΎΡΠ° ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΠΈ Π³Π΅ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ Π½ΠΈΠ·ΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ … Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ
- 1. ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠΉ ΠΎΠ±Π·ΠΎΡ
- 1. 1. Π‘ΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·
- 1. 1. 1. ΠΠ±ΡΠΈΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·Π°Ρ
- 1. 1. 2. Π‘ΡΡΡΠΊΡΡΡΠ° ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·
- 1. 1. 3. ΠΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠΈΠ½Π°Π·
- 1. 1. 4. ΠΠ’Π€-ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΡΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π· ΠΈ ΠΈΡ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ
- 1. 2. ΠΠ΅ΡΠΎΠ΄ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΠΊΠΈΠ½Π³Π°
- 1. 2. 1. Π’Π΅ΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠ½ΠΎΠ²Ρ ΠΌΠ΅ΡΠΎΠ΄Π°
- 1. 2. 2. ΠΠ΅ΡΠΎΠ΄Ρ ΡΠΊΠ°Π½ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ²Π΅ΡΡ Π½ΠΎΡΡΠΈ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ
- 1. 3. Π Π°ΡΡΠ΅Ρ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΡ
- 1. 3. 1. ΠΠ΅ΡΠΎΠ΄ Π²ΠΎΠ·ΠΌΡΡΠ΅Π½ΠΈΠΉ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ
- 1. 3. 2. ΠΠ΅ΡΠΎΠ΄Ρ Π»ΠΈΠ½Π΅ΠΉΠ½ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ
- 1. 3. 3. ΠΡΠΈΠ±Π»ΠΈΠΆΠ΅Π½ΠΈΡ Π°Π΄Π΄ΠΈΡΠΈΠ²Π½ΡΡ Π²ΠΊΠ»Π°Π΄ΠΎΠ² Π² ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ ΡΠ½Π΅ΡΠ³ΠΈΡ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΡ
- 1. 3. 4. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΌΠΏΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΉ
- 1. 4. ΠΠΈΡΡΡΠ°Π»ΡΠ½ΡΠΉ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³
- 1. 4. 1. ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅
- 1. 4. 2. ΠΠ΅ΡΠΎΠ΄ ΡΡΡΡΠΊΡΡΡΠ½ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ
- 1. 5. Π€ΡΠ°Π³ΠΌΠ΅Π½ΡΠ°ΠΌΠΈ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ ΠΊ ΠΏΠΎΠΈΡΠΊΡ Π½ΠΎΠ²ΡΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²
- 1. 5. 1. Π‘ΠΎΠ·Π΄Π°Π½ΠΈΠ΅ Π»Π΅ΠΊΠ°ΡΡΡΠ² Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ° Π΄Π΅ΠΉΡΡΠ²ΠΈΡ
- 1. 5. 2. ΠΡΠΈΠΌΠ΅ΡΡ ΠΏΠΎΠΈΡΠΊΠ° Π»Π΅ΠΊΠ°ΡΡΡΠ² Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Π°
- 1. 1. Π‘ΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·
- 2. 1. ΠΠΎΠΌΠΏΡΡΡΠ΅ΡΠ½ΡΠ΅ ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΡ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Π½ΡΠ΅ Π² ΡΠ°Π±ΠΎΡΠ΅
- 2. 2. ΠΠΎΡΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ ΡΡΠ΅Ρ ΠΌΠ΅ΡΠ½ΠΎΠΉ ΡΡΡΡΠΊΡΡΡΡ Π±Π΅Π»ΠΊΠΎΠ²
- 2. 3. ΠΠΎΡΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ ΡΡΠ΅Ρ ΠΌΠ΅ΡΠ½ΡΡ ΡΡΡΡΠΊΡΡΡ Π»ΠΈΠ³Π°Π½Π΄ΠΎΠ²
- 2. 4. Π Π°Π·Π±ΠΈΠ΅Π½ΠΈΠ΅ ΠΌΠΎΠ»Π΅ΠΊΡΠ» ΠΈΠ·Π²Π΅ΡΡΠ½ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ² Π½Π° ΡΡΠ°Π³ΠΌΠ΅Π½ΡΡ
- 2. 5. ΠΠΎΠΊΠΈΠ½Π³ ΠΈ Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΡΠΉ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³
- 2. 6. ΠΡΠ΅Π½ΠΊΠ° ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² Π±Π΅Π»ΠΎΠΊ-Π»ΠΈΠ³Π°Π½Π΄
- 2. 7. Π Π°ΡΡΠ΅Ρ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·
- 2. 8. Π‘ΡΡΡΠΊΡΡΡΠ½Π°Ρ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 2. 9. Π Π°Π½ΠΆΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 2. 10. Π Π°ΡΡΠ΅Ρ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΎΠ±ΠΎΠ³Π°ΡΠ΅Π½ΠΈΡ Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 2. 11. ΠΠΈΠ·ΡΠ°Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· Π³Π΅ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² Π±Π΅Π»ΠΎΠΊ-Π»ΠΈΠ³Π°Π½Π΄
- 2. 12. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠΎΡΠΎΠ² ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ²
- 2. 13. ΠΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ-ΠΌΠΈΡΠ΅Π½ΡΠΌΠΈ
- 2. 13. 1. ΠΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·Ρ ΠΡΠ¬Π2 ΠΈ ΠΠ‘Π
- 2. 13. 2. ΠΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·Π° Π‘ΠΠ
- 2. 13. 3. ΠΡΡΠ°Π½ΡΠ½Π°Ρ ΡΠΎΡΠΌΠ° ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·Ρ ABL1 T
- 3. 1. ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π· Ρ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ
- 3. 1. 1. ΠΠΎΡΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ»Π½ΠΎΠ°ΡΠΎΠΌΠ½ΡΡ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ Π±Π΅Π»ΠΊΠΎΠ²
- 3. 1. 1. ΠΠΎΡΡΡΠΎΠ΅Π½ΠΈΠ΅ ΡΡΠ΅Ρ ΠΌΠ΅ΡΠ½ΡΡ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ Π»ΠΈΠ³Π°Π½Π΄ΠΎΠ²
- 3. 1. 3. ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ»Π΅ΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·
- 3. 1. 4. ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΏΠ΅ΠΊΡΡΠ° Π²ΠΎΡΠΏΡΠΈΠΈΠΌΡΠΈΠ²ΠΎΡΡΠΈ ΠΊΠΈΠ½Π°Π· ΠΊ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌ
- 3. 1. 5. Π£ΡΠΎΡΠ½Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΉ Π±ΠΎΠΊΠΎΠ²ΡΡ ΡΠ°Π΄ΠΈΠΊΠ°Π»ΠΎΠ²
- 3. 1. 6. ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ»Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΊΠΈΠ½Π°Π·Π½ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ²
- 3. 1. 7. ΠΠ°Π²ΠΈΡΠΈΠΌΠΎΡΡΡ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΡΡΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° ΠΎΡ Π΅Π³ΠΎ ΡΠΈΠΏΠ° ΠΈ ΠΊΠΎΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΡΠ΅Π½ΡΡΠ° ΠΊΠΈΠ½Π°Π·Ρ
- 3. 2. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΎΡΠ½ΠΎΡΡΠΈ Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 3. 2. 1. ΠΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΡΠ΅ΡΡΠΎΠ²ΠΎΠ³ΠΎ Π½Π°Π±ΠΎΡΠ° DUD
- 3. 2. 2. ΠΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ° ΠΏΠΎΠ»Π½ΠΎΠ°ΡΠΎΠΌΠ½ΡΡ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ Π±Π΅Π»ΠΊΠΎΠ²
- 3. 2. 3. ΠΡΠΈΡΠ΅ΡΠΈΠΈ ΡΡΡΡΠΊΡΡΡΠ½ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 3. 2. 4. ΠΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ° Π±ΠΈΠ±Π»ΠΈΠΎΡΠ΅ΠΊ Π»ΠΈΠ³Π°Π½Π΄ΠΎΠ²
- 3. 2. 5. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΎΡΠ½ΠΎΡΡΠΈ Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 3. 2. 6. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΡΠ²ΠΎΠΉΡΡΠ² Π±Π΅Π»ΠΊΠΎΠ² Π½Π° ΡΠΎΡΠ½ΠΎΡΡΡ Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 3. 2. 7. Π‘ΡΡΡΠΊΡΡΡΠ½Π°Ρ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 3. 3. ΠΠΎΠΈΡΠΊ Π½ΠΎΠ²ΡΡ
ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΡ
ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² EphA2 ΠΈ ΠΠ‘Π
- 3. 3. 1. ΠΠΎΡΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠ»Π½ΠΎΠ°ΡΠΎΠΌΠ½ΡΡ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ Π±Π΅Π»ΠΊΠΎΠ²
- 3. 3. 2. ΠΠΎΡΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΌΠΎΠ΄Π΅Π»Π΅ΠΉ ΡΡΠ΅Ρ ΠΌΠ΅ΡΠ½ΡΡ ΡΡΡΡΠΊΡΡΡ Π»ΠΈΠ³Π°Π½Π΄ΠΎΠ²
- 3. 3. 3. ΠΠ½Π°Π»ΠΈΠ· ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² EphA2 ΠΈ ΠΠ‘Π
- 3. 3. 4. ΠΠΎΠΈΡΠΊ Π½ΠΎΠ²ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΠ‘Π1 ΠΈ EphA2 ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π²ΠΈΡΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π°
- 3. 4. ΠΠ°Π»ΠΈΠ΄ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π° ΠΊ ΠΏΠΎΠΈΡΠΊΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² in silico
- 3. 4. 1. Π€Π°ΠΊΡΠΎΡΡ, Π²Π»ΠΈΡΡΡΠΈΠ΅ Π½Π° ΡΠΎΡΠ½ΠΎΡΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΠΊΠΈΠ½Π³Π° ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ² Π»Π΅ΠΊΠ°ΡΡΡΠ²
- 3. 4. 2. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΈ ΡΠ°ΡΡΠ΅ΡΠ½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΡΠ²ΡΠ·ΡΠ²Π°Π½ΠΈΡ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠ²
- 3. 4. 3. ΠΠΎΠΈΡΠΊ Π½ΠΎΠ²ΡΡ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π· CDK2 ΠΈ ABL
- 3. 4. 4. ΠΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½Π°Ρ ΠΏΡΠΎΠ²Π΅ΡΠΊΠ° ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½Π½ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ²
ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΌΠΈΡΠ΅Π½ΡΠΌΠΈ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠΎΠΌΠΈΠΌΠΎ ΡΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Π° ΠΊ ΠΏΠΎΠΈΡΠΊΡ Π½ΠΎΠ²ΡΡ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π½Π° ΡΠ΅Π½ΠΎΡΠΈΠΏΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π΅, Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ Π±ΠΎΠ»ΡΡΠΎΠ΅ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠΈΠ» Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΠΉ ΠΏΠΎΠΈΡΠΊ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ², Π΄Π΅ΠΉΡΡΠ²ΡΡΡΠΈΡ Π½Π° Π·Π°ΡΠ°Π½Π΅Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΡΡ Π±Π΅Π»ΠΊΠΎΠ²ΡΡ (ΡΠ΅ΡΠΌΠ΅Π½Ρ, ΡΠ΅ΡΠ΅ΠΏΡΠΎΡ, .) ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΡΡ ΠΌΠΈΡΠ΅Π½Ρ. ΠΠ»Ρ ΡΡΠΏΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠΈΡΠΊΠ° ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΡ Π·Π°Π΄Π°Π½Π½ΡΠΌΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²Π°ΠΌΠΈ, Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΠ΅Π»ΡΡ ΠΎΠ±Π»Π°ΡΡΠ΅ΠΉ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ Π·Π½Π°Π½ΠΈΡ Π½Π° ΡΡΡΠΊΠ΅ Ρ ΠΈΠΌΠΈΠΈ, ΡΠΈΠ·ΠΈΠΊΠΈ ΠΈ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ.
ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΡΡΡΠΊΡΡΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ, Π² Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΈΠ·Π²Π΅ΡΡΠ½Ρ ΡΡΠ΅Ρ ΠΌΠ΅ΡΠ½ΡΠ΅ ΡΡΡΡΠΊΡΡΡΡ ΠΌΠ½ΠΎΠ³ΠΈΡ Π±Π΅Π»ΠΊΠΎΠ², Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΠ²Π»ΡΡΡΠΈΡ ΡΡ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΌΠΈΡΠ΅Π½ΡΠΌΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ. Π Π°ΡΠΏΠΎΠ»Π°Π³Π°Ρ ΡΡΡΡΠΊΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠ΅ΠΉ, ΠΌΠΎΠΆΠ½ΠΎ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΡΠ΅ΠΎΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Ρ ΠΈΠΌΠΈΠΈ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°ΡΡ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ ΡΠ½Π΅ΡΠ³ΠΈΡ ΠΈ Π³Π΅ΠΎΠΌΠ΅ΡΡΠΈΡ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Π² Π°ΠΊΡΠΈΠ²Π½ΡΡ ΡΠ΅Π½ΡΡΠ°Ρ Π±Π΅Π»ΠΊΠΎΠ², ΠΈ ΡΠ°ΡΡΡΠΈΡΡΠ²Π°ΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ ΠΈΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ ΠΌΠΈΡΠ΅Π½ΠΈ Π²ΡΠ±ΡΠ°Π½Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΎΡΠΈΠ»Ρ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠΎ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ ΠΎΡΡΠ°Π»ΡΠ½ΡΠΌ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠΈΡΠ΅Π½ΡΠΌ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²ΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, ΠΎΠ΄Π½Π°ΠΊΠΎ ΡΠΎΡ ΡΠ°ΠΊΡ, ΡΡΠΎ Π²ΠΎ ΠΌΠ½ΠΎΠ³ΠΈΡ ΡΠ»ΡΡΠ°ΡΡ ΠΈΡ ΡΠΎΡΠ½ΠΎΡΡΡ ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅ΡΡΡ Π½Π΅ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ, Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅Ρ Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ².
ΠΠ°ΡΡΠΎΡΡΠ°Ρ ΡΠ°Π±ΠΎΡΠ° ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΠΈ Π³Π΅ΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ Π½ΠΈΠ·ΠΊΠΎΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΌΠΈΡΠ΅Π½ΡΠΌΠΈ Π² Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠΌ ΠΏΠΎΠΈΡΠΊΠ΅ Π½ΠΎΠ²ΡΡ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ».
Π ΡΠ°Π±ΠΎΡΠ΅ ΠΏΡΠ΅ΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈΡΡ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ΅Π»ΠΈ:
β’ ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΡΡΠΊΡΡΡ ΠΈ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ ΡΠ½Π΅ΡΠ³ΠΈΠΉ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² ΠΊΠΈΠ½Π°Π· Ρ ΠΈΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΠΊΠΈΠ½Π³Π° Π΄Π»Ρ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΡ ΡΠ΅Π»Π΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΊΠΈΠ½Π°Π·Π½ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ².
β’ ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ°ΠΊΡΠΎΡΠΎΠ², Π²Π»ΠΈΡΡΡΠΈΡ Π½Π° ΡΠΎΡΠ½ΠΎΡΡΡ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ ΠΎΡΠ³Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄ΠΎΠΊΠΈΠ½Π³Π° ΠΏΡΠΈΠΌΠ΅Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎ ΠΊ ΠΏΠΎΠΈΡΠΊΡ Π½ΠΎΠ²ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, Π² ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ — ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΡΠ²ΡΠ·ΡΠ²Π°ΡΡΠΈΡ ΡΡ Ρ Π·Π°Π΄Π°Π½Π½ΡΠΌ Π±Π΅Π»ΠΊΠΎΠΌ — ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΌΠΈΡΠ΅Π½ΡΡ.
β’ ΠΠ°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΠΉ ΠΏΠΎΠΈΡΠΊ Π½ΠΎΠ²ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΡΠΏΠΎΡΠΎΠ±Π½ΡΡ ΠΊ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠ°ΡΠ°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠ² ΠΊΠΈΠ½Π°Π·.
1. ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ½ΡΠΉ ΠΎΠ±Π·ΠΎΡ
4. ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ Π²ΡΠ²ΠΎΠ΄Ρ.
1. ΠΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΡΡΡΡΠΊΡΡΡΠ½ΡΡ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΎΠ² ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ Π½Π°Π±ΠΎΡΠ° 86 ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠ² ΠΊΠΈΠ½Π°Π· ΠΈ ΠΈΡ 42 ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΠΊΠΈΠ½Π³Π° Π΄Π°Π»ΠΎ ΠΎΠ±ΡΡΡ ΡΠΎΡΠ½ΠΎΡΡΡ 77% Π² ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠΈ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΡ ΠΏΠ°Ρ ΡΠ΅ΡΠΌΠ΅Π½Ρ-ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡ.
2. ΠΠ΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΡ Π΄Π°Π½Π½ΡΡ ΠΎ ΡΡΡΡΠΊΡΡΡΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΡΡ ΡΠ΅Π½ΡΡΠΎΠ² ΠΊΠΈΠ½Π°Π· ΠΈ ΠΈΡ ΠΏΠΎΠ΄Π²ΠΈΠΆΠ½ΠΎΡΡΠΈ ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»ΠΈΠ²Π°Π΅Ρ Π±ΠΎΠ»ΡΡΡΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΡΡΡ ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΡ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΠΉ (85%) ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ (52%) Π΄Π»Ρ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ ΠΏΠ°Ρ ΡΠ΅ΡΠΌΠ΅Π½Ρ-ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄ΠΎΠΊΠΈΠ½Π³Π°.
3. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄Π° ΡΡΡΡΠΊΡΡΡΠ½ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ½ΠΈΠ·ΠΈΡΡ Π½Π°ΡΠ°Π»ΡΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅Π½Ρ Π»ΠΎΠΆΠ½ΠΎΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π°Π½ΠΈΠΉ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ ΠΏΠ°Ρ Π±Π΅Π»ΠΎΠΊ-Π»ΠΈΠ³Π°Π½Π΄ Π² 1.5 ΡΠ°Π·Π°, ΠΊΠ°ΠΊ Π±ΡΠ»ΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ Π½Π° Π½Π°Π±ΠΎΡΠ΅ 40 ΡΡΡΡΠΊΡΡΡΠ½ΠΎ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ².
4. ΠΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄Π½ΡΡ 2-Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈΡΠ΅Π½ΠΎΠ»Π° ΠΊΠΎΠΎΡΠ΄ΠΈΠ½ΠΈΡΠΎΠ²Π°ΡΡΡΡ Π² Π°ΠΊΡΠΈΠ²Π½ΠΎΠΌ ΡΠ΅Π½ΡΡΠ΅ ΡΠΈΡΠΎΠ·ΠΈΠ½ΠΊΠΈΠ½Π°Π· ΠΡΠ¬Π2 ΠΈ ΠΠ‘Π1 ΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°ΡΡ ΠΈΡ ΡΠ΅ΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠ²Π½ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π² ΠΌΠΈΠΊΡΠΎΠΌΠΎΠ»ΡΡΠ½ΠΎΠΌ Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ. ΠΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° ΠΈΠ½Π³ΠΈΠ±ΠΈΡΡΡΡΠ°Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π½Π°ΠΉΠ΄Π΅Π½Π½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Π² ΡΡΠ΄Ρ 20 ΡΠΈΡΠΎΠ·ΠΈΠ½ΠΊΠΈΠ½Π°Π· ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°.
5. ΠΠ°ΠΈΠ±ΠΎΠ»ΡΡΠ°Ρ ΡΠΎΡΠ½ΠΎΡΡΡ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΡΡΠΊΡΡΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² Π±Π΅Π»ΠΊΠΎΠ² Ρ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΠΌΠΈ ΠΎΡΠ³Π°Π½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΡΠΌΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄ΠΎΠΊΠΈΠ½Π³Π° ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 83% ΠΈ Π΄ΠΎΡΡΠΈΠ³Π°Π΅ΡΡΡ Π΄Π»Ρ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ, ΡΡΠ°ΡΡΠ²ΡΡΡΠΈΡ Π² Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡΡ (Π²ΠΎΠ΄ΠΎΡΠΎΠ΄Π½ΡΠ΅ ΡΠ²ΡΠ·ΠΈ, ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΡ Ρ ΠΌΠ΅ΡΠ°Π»Π»ΠΎΠΌ ΠΈ Ρ. Π΄.) ΠΈ ΠΎΠ±ΡΠ°Π·ΡΡΡΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΌΠ΅Π½ΡΠ°ΡΠ½ΡΠΉ Π³ΠΈΠ΄ΡΠΎΡΠΎΠ±Π½ΡΠΉ ΠΊΠΎΠ½ΡΠ°ΠΊΡ Ρ Π±Π΅Π»ΠΊΠΎΠΌ. Π’ΠΎΡΠ½ΠΎΡΡΡ ΡΠ°ΡΡΠ΅ΡΠ° ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ, ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½Π°Ρ Π½Π° Π½Π°Π±ΠΎΡΠ΅ 68 ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ², ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ 1,35 ΠΊΠΊΠ°Π»/ΠΌΠΎΠ»Ρ.
6. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΡΡΠΊΡΡΡΠ½ΠΎΠΉ ΡΠΈΠ»ΡΡΡΠ°ΡΠΈΠΈ ΠΈ ΠΊΠ»Π°ΡΡΠ΅ΡΠΈΠ·Π°ΡΠΈΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΠΎΡΠ½ΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π΄ΠΎΠΊΠΈΠ½Π³Π° Π΄Π»Ρ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΎΡΠ΄ΠΈΠ½Π°ΡΠΈΠΈ ΠΈ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎΠΉ ΡΠ½Π΅ΡΠ³ΠΈΠΈ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ½ΡΡ ΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠΉ Ρ Π±Π΅Π»ΠΊΠ°ΠΌΠΈ, ΠΈ Π½Π°ΠΉΡΠΈ 4 Π½ΠΎΠ²ΡΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ° ΠΏΡΠΎΡΠ΅ΠΈΠ½ΠΊΠΈΠ½Π°Π·Ρ Π‘ΠΠ2 Ρ ΠΊΠΎΠ½ΡΡΠ°Π½ΡΠ°ΠΌΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΠ²Π°Π½ΠΈΡ, Π»Π΅ΠΆΠ°ΡΠΈΠΌΠΈ Π² ΠΌΠΈΠΊΡΠΎΠΌΠΎΠ»ΡΡΠ½ΠΎΠΌ Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Hunter, T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling / T. Hunter // Cell. — 1995. — Vol. 80, № 2. — P. 225−36.
- Johnson, L. N. Structural basis for control by phosphorylation / L. N. Johnson, R. J. Lewis // Chem. Rev. — 2001. — Vol. 101, № 8. — P. 2209−42.
- Neel, B. G. Protein tyrosine phosphatases in signal transduction / B. G. Neel, N. K. Tonks // Curr. Opin. Cell Biol. — 1997. — Vol. 9, № 2. — P. 193−204.
- Saito, H. Histidine phosphorylation and two-component signaling in eukaryotic cells / H. Saito // Chem. Rev. — 2001. — Vol. 101, № 8. — P. 2497−509.
- Schlessinger, J. Growth factor signaling by receptor tyrosine kinases / J. Schlessinger, A. Ullrich//Neuron. — 1992. — Vol. 9, № 3. — P. 383−91.
- Hubbard, S. R. Protein tyrosine kinase structure and function / S. R. Hubbard, J. H. Till // Annu. Rev. Biochem. — 2000. — Vol. 69. — P. 373−98.
- Chen, Z. MAP kinases / Z. Chen, T. B. Gibson, F. Robinson et al. // Chem. Rev. — 2001.
- Vol. 101, № 8. — P. 2449−76.
- Knighton, D. R. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase / D. R. Knighton, J. H. Zheng, L. F. Ten Eyck et al. // Science. — 1991. — Vol. 253, № 5018. — P. 414−20.
- Hanks, S. K. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification / S. K. Hanks, T. Hunter // FASEB J. — 1995. — Vol. 9, № 8. —P. 576−96.
- Johnson, L. N. Active and inactive protein kinases: structural basis for regulation / L. N. Johnson, M. E. Noble, and D. J. Owen// Cell. — 1996. — Vol. 85, № 2. — P. 149−58.
- Adams, J. A. Kinetic and catalytic mechanisms of protein kinases / J. A. Adams // Chem. Rev. —2001. — Vol. 101, № 8. — P. 2271−90.
- Robertson, S. C. RTK mutations and human syndromes: when good receptors turn bad / S. C. Robertson, J. Tynan, and D. J. Donoghue // Trends Genet. — 2000. — Vol. 16, № 8.1. P. 368.
- Muller-Ladner, U. Molecular and cellular interactions in rheumatoid synovium / U. MullerLadner // Curr. Opin. Rheumatol. — 1996. — Vol. 8, № 3. — P. 210−20.
- Taylor, S. S. Protein kinase inhibition: natural and synthetic variations on a theme / S. S. Taylor, E. Radzio-Andzelm // Curr. Opin. Chem. Biol. — 1997. — Vol. 1, № 2. — P. 21 926.
- Toledo, L. M. The structure-based design of ATP-site directed protein kinase inhibitors / L. M. Toledo, N. B. Lydon, and D. Elbaum // Curr. Med. Chem. — 1999. — Vol. 6, № 9. — P. 775−805.
- Broadbridge, R. J. The Src homology-2 domains (SH2 domains) of the protein tyrosine kinase p561ck: structure, mechanism and drug design / R. J. Broadbridge, R. P. Sharma //178
- Curr. Drug Targets. — 2000. — Vol. 1, № 4. — P. 365−86.
- Lawrence, D. S. Protein kinase inhibitors: the tyrosine-specific protein kinases / D. S. Lawrence, J. Niu // Pharmacol. Ther. — 1998. — Vol. 77, № 2. — P. 81−114.
- Blum, G. Substrate competitive inhibitors of IGF-1 receptor kinase / G. Blum, A. Gazit, and A. Levitzki // Biochemistry. — 2000. — Vol. 39, № 51. — P. 15 705−12.
- Bridges, A. J. Chemical inhibitors of protein kinases / A. J. Bridges // Chem. Rev. — 2001. — Vol. 101, № 8, —P. 2541−72.
- Sausville, E. A. Protein kinase antagonists: interim challenges and issues / E. A. Sausville // Anticancer Drug Des. — 2000. — Vol. 15, № 1. — P. 1−2.
- Wang, Z. Structural basis of inhibitor selectivity in MAP kinases / Z. Wang, B. J. Canagarajah, J. C. Boehm et al. // Structure. — 1998. — Vol. 6, № 9. — P. 1117−28.
- Zhu, X. Structural analysis of the lymphocyte-specific kinase Lck in complex with nonselective and Src family selective kinase inhibitors / X. Zhu, J. L. Kim, J. R. Newcomb et al. // Structure. — 1999. — Vol. 7, № 6. — P. 651−61.
- Brooks, G. The cell cycle and drug discovery: the promise and the hope / G. Brooks, N. B. La Thangue // Drug Discov. Today. — 1999. — Vol. 4, № 10. — P. 455−464.
- Lapenna, S. Cell cycle kinases as therapeutic targets for cancer / S. Lapenna, A. Giordano // Nat. Rev. Drug Discov. — 2009. — Vol. 8, № 7. — P. 547−566.
- Furet, P. Structure-based design of potent CDK1 inhibitors derived from olomoucine / P. Furet, J. Zimmermann, H. G. Capraro et al. // J. Comput. Aided Mol. Des. — 2000. — Vol. 14, № 5. —P. 403−9.
- Krause, D. S. Tyrosine kinases as targets for cancer therapy / D. S. Krause, R. A. Van Etten // N. Engl. J. Med. — 2005. — Vol. 353, № 2. — P. 172−87.
- Salih, J. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity / J. Salih, J. Hilpert, T. Placke et al. // Int. J. Cancer. — 2010. — Vol. 127, № 9. —P. 2119−28.
- Traxler, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors / P. Traxler, P. Furet // Pharmacol. Ther. — 1999. — Vol. 82, № 2−3. — P. 195 206.
- Schindler, T. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase / T. Schindler, W. Bornmann, P. Pellicena et al. // Science. — 2000. — Vol. 289, № 5486. — P. 1938−42.
- Totrov, M. Flexible protein-ligand docking by global energy optimization in internal coordinates / M. Totrov, R. Abagyan // Proteins. — 1997. — Vol. Suppl 1, β. — P. 215−20.
- Tietze, S. GlamDock: Development and Validation of a New Docking Tool on Several Thousand Protein-Ligand Complexes / S. Tietze, J. Apostolakis // J. Chem. Inf. Model. — 2007. — Vol. 47, № 4. — P. 1657−1672.
- Morris, G. M. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function / G. M. Morris, D. S. Goodsell, R. S. Halliday et al. // Journal of Computational Chemistry. — 1998. — Vol. 19, № 14. — P. 1639−1662.
- Huey, R. A semiempirical free energy force field with charge-based desolvation / R. Huey, G. M. Morris, A. J. Olson et al. // J. Comput. Chem. — 2007. — Vol. 28, № 6. — P. 114 552.
- Jones, G. Development and validation of a genetic algorithm for flexible docking / G. Jones, P. Willett, R. C. Glen et al. // J. Mol. Biol. — 1997. — Vol. 267, № 3. — P. 727−48.
- Hartshorn, M. J. Diverse, high-quality test set for the validation of protein-ligand docking performance / M. J. Hartshorn, M. L. Verdonk, G. Chessari et al. // J. Med. Chem. — 2007. — Vol. 50, № 4. — P. 726−41.
- Thomsen, R. MolDock: a new technique for high-accuracy molecular docking / R. Thomsen, M. H. Christensen//J. Med. Chem. — 2006. — Vol. 49, № 11. —P. 3315−21.
- Oshiro, C. M. Flexible ligand docking using a genetic algorithm / C. M. Oshiro, I. D. Kuntz, and J. S. Dixon // J. Comput. Aided Mol. Des. — 1995. — Vol. 9, № 2. — P. 113−30.
- Rarey, M. Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention / M. Rarey, B. Kramer, and T. Lengauer // J. Comput. Aided Mol. Des. — 1997. — Vol. 11, № 4. — P. 369−84.
- Kramer, B. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking / B. Kramer, M. Rarey, and T. Lengauer // Proteins. — 1999. — Vol. 37, № 2. — P. 228−41.
- Jain, A. N. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine / A. N. Jain // J. Med. Chem. — 2003. — Vol. 46, № 4. — P. 499−511.
- Goodsell, D. S. Automated docking of substrates to proteins by simulated annealing / D. S. Goodsell, A. J. Olson // Proteins. — 1990. — Vol. 8, № 3. — P. 195−202.
- Solis, F. J. Minimization by Random Search Techniques / F. J. Solis, R. J. B. Wets // Math. Oper. Res. — 1981. — Vol. 6, № 1. — P. 19−30.
- Gohlke, H. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors / H. Gohlke, G. Klebe // Angew. Chem. Int. Edit. — 2002. — Vol. 41, № 15. — P. 2645−2676.
- Reddy, M. R. Free energy calculations in rational drug design / M. R. Reddy, M. D. Erion. — New York: Kluwer Academic/Plenum Publishers, 2001. 384 p. — ISBN 306 466 767.
- Shirts, M. R. Comparison of efficiency and bias of free energies computed by exponential averaging, the Bennett acceptance ratio, and thermodynamic integration / M. R. Shirts, V. S.
- Pande // J. Chem. Phys. — 2005. — Vol. 122, № 14. — P. 144 107.
- Pearlman, D. A. The lag between the Hamiltonian and the system configuration in free energy perturbation calculations / D. A. Pearlman, P. A. Kollman // J. Chem. Phys. — 1989. — Vol. 91, № 12, —P. 7831−7839.
- Straatsma, T. P. Multiconfiguration thermodynamic integration / T. P. Straatsma, J. A. McCammon // J. Chem. Phys. — 1991. — Vol. 95, № 2. — P. 1175−1188.
- Hendrix, D. A. A «fast growth» method of computing free energy differences / D. A. Hendrix, C. Jarzynski // J. Chem. Phys. —2001. — Vol. 114, № 14. — P. 5974−5981.
- Warshel, A. Dynamics of reactions in polar solvents. Semiclassical trajectory studies of electron-transfer and proton-transfer reactions / A. Warshel // J. Phys. Chem. — 1982. — Vol. 86, № 12. — P. 2218−2224.
- Sham, Y. Y. Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA, and PDLD/S-LRA calculations of ligands binding to an HIV protease / Y. Y. Sham, Z. T. Chu, H. Tao et al. // Proteins. — 2000. — Vol. 39, № 4. — P. 393−407.
- Aqvist, J. A new method for predicting binding affinity in computer-aided drug design / J. Aqvist, C. Medina, and J. E. Samuelsson // Protein Eng. — 1994. — Vol. 7, № 3. — P. 38 591.
- Hansson, T. Ligand binding affinity prediction by linear interaction energy methods / T. Hansson, J. Marelius, and J. Aqvist // Journal of Computer-Aided Molecular Design. —1998. — Vol. 12, № 1. —P. 27−35.
- Wall, I. D. Binding constants of neuraminidase inhibitors: An investigation of the linear interaction energy method / I. D. Wall, A. R. Leach, D. W. Salt et al. // J. Med. Chem. —1999. — Vol. 42, № 25. — P. 5142−52.
- Carlson, H. A. An Extended Linear Response Method for Determining Free Energies of Hydration / H. A. Carlson, W. L. Jorgensen // J. Phys. Chem. — 1995. — Vol. 99, № 26. — P. 10 667−10 673.
- Lee, B. The interpretation of protein structures: estimation of static accessibility / B. Lee, F. M. Richards // J. Mol. Biol. — 1971. — Vol. 55, № 3. — P. 379−400.
- Hermann, R. B. Theory of hydrophobic bonding. II. Correlation of hydrocarbon solubility in181water with solvent cavity surface area / R. B. Hermann // J. Phys. Chem. — 1972. — Vol. 76, № 19. — P. 2754−2759.
- Sitkoff, D. Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models / D. Sitkoff, K. A. Sharp, and B. Honig // J. Phys. Chem. — 1994. — Vol. 98, № 7.1. P. 1978−1988.
- Lavigne, P. Structure-based thermodynamic analysis of the dissociation of protein phosphatase-1 catalytic subunit and microcystin-LR docked complexes / P. Lavigne, J. R. Bagu, R. Boyko et al. // Protein Sci. — 2000. — Vol. 9, № 2. — P. 252−64.
- Stouten, P. F. W. An Effective Solvation Term Based on Atomic Occupancies for Use in Protein Simulations / P. F. W. Stouten, C. Frommel, H. Nakamura etal. // Molecular Simulation. — 1993. — Vol. 10, № 2. — P. 97−120.
- Baker, N. A. Poisson-Boltzmann methods for biomolecular electrostatics / N. A. Baker // Methods Enzymol. — 2004. — Vol. 383, β. — P. 94−118.
- Bashford, D. Generalized born models of macromolecular solvation effects / D. Bashford,
- D. A. Case // Annu. Rev. Phys. Chem. — 2000. — Vol. 51, β. — P. 129−52.
- Mehler, E. L. Electrostatic effects in proteins: comparison of dielectric and charge models /
- E. L. Mehler, T. Solmajer // Protein Eng. — 1991. — Vol. 4, № 8. — P. 903−10.
- Mehler, E. L. The role of hydrophobic microenvironments in modulating pKa shifts in proteins / E. L. Mehler, M. Fuxreiter, I. Simon et al. // Proteins. — 2002. — Vol. 48, № 2.1. P. 283−92.
- Bohm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure / H. J. Bohm // J. Comput. Aided Mol. Des. — 1994. — Vol. 8, № 3. — P. 243−56.
- Gohlke, H. Knowledge-based scoring function to predict protein-ligand interactions / H. Gohlke, M. Hendlich, and G. Klebe // J. Mol. Biol. — 2000. — Vol. 295, № 2. — P. 337−56.
- Friesner, R. A. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes / R. A. Friesner, R. B. Murphy, M. P. Repasky et al. // J. Med. Chem. — 2006. — Vol. 49, № 21. — P. 6177−96.
- Brooks, B. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations / B. Brooks, R. Bruccoleri, B. Olafson et al. // J. Comput. Chem. — 1983. — Vol. 4, № 2. —P. 187−217.
- Mehler, E. L. A self-consistent, microenvironment modulated screened coulomb potential approximation to calculate pH-dependent electrostatic effects in proteins / E. L. Mehler, F.182
- Guarnieri // Biophys. J. — 1999. — Vol. 77, № 1. — P. 3−22.
- Shoichet, B. K. Virtual screening of chemical libraries / B. K. Shoichet // Nature. — 2004.
- Vol. 432, № 7019. — P. 862−5.
- Rester, U. From virtuality to reality Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective / U. Rester // Curr. Opin. Drug Discov. Devel. —2008.—Vol. 11,№ 4, —P. 559−68.
- Rollinger, J. M. Virtual screening for the discovery of bioactive natural products / J. M. Rollinger, H. Stuppner, and T. Langer // Prog. Drug Res. — 2008. — Vol. 65, β. — P. 211, 213−49.
- Waszkowycz, B. Large-scale virtual screening for discovering leads in the postgenomic era / B. Waszkowycz, T. D. J. Perkins, R. A. Sykes et al. // IBM Syst. J. — 2001. — Vol. 40, β.1. P. 360−376.
- Berman, H. M. The Protein Data Bank / H. M. Berman, J. Westbrook, Z. Feng et al. // Nucleic Acids Res. — 2000. — Vol. 28, № 1. — P. 235−42.
- Reiss, T. Drug discovery of the future: the implications of the human genome project / T. Reiss // Trends Biotechnol. — 2001. — Vol. 19, № 12. — P. 496−9.
- Stahura, F. L. Virtual screening methods that complement HTS / F. L. Stahura, J. Bajorath // Comb. Chem. High Throughput Screen. — 2004. — Vol. 7, № 4. — P. 259−69.
- Schneider, G. Virtual screening and fast automated docking methods / G. Schneider, H. J. Bohm // Drug Discov. Today. — 2002. — Vol. 7, № 1. — P. 64−70.
- Koppen, H. Virtual screening what does it give us? / H. Koppen // Curr. Opin. Drug Discov. Devel. — 2009. — Vol. 12, № 3. — P. 397−407.
- Leach, A. R. An Introduction to Chemoinformatics. / A. R. Leach, V. J. Gillet. Springer, 2003.-255 p. — ISBN 978−1-4020−1347−8.
- Cross, J. B. Comparison of several molecular docking programs: pose prediction and virtual screening accuracy / J. B. Cross, D. C. Thompson, B. K. Rai et al. // J. Chem. Inf. Model.2009. — Vol. 49, № 6. — P. 1455−74.
- Novikov, F. N. Improving performance of docking-based virtual screening by structural filtration / F. N. Novikov, V. S. Stroylov, O. V. Stroganov et al. // J. Mol. Model. — 2010.
- Vol. 16, № 7. — P. 1223−30.
- Krogsgaard-Larsen, P. Textbook of Drug Design and Discovery, 3rdEdition. London and New York: Tayor and Francis, 2002 / P. Krogsgaard-Larsen, T. Liljefors, and U. Madsen // Journal of Pharmacy and Pharmacology. — 2003. — Vol. 55, № 10. — P. 1449−1449.
- Warr, W. Fragment-based drug discovery / W. Warr // Journal of Computer-Aided Molecular Design. — 2009. — Vol. 23, № 8. — P. 453−458.
- Hajduk, P. J. A decade of fragment-based drug design: strategic advances and lessons learned / P. J. Hajduk, J. Greer // Nat. Rev. Drug Discov. — 2007. — Vol. 6, № 3. — P. 2119.
- Hann, M. M. Pursuing the leadlikeness concept in pharmaceutical research / M. M. Hann, T.
- Oprea // Curr. Opin. Chem. Biol. — 2004. — Vol. 8, № 3. — P. 255−63.
- Congreve, M. Recent developments in fragment-based drug discovery / M. Congreve, G. Chessari, D. Tisi et al. // J. Med. Chem. — 2008. — Vol. 51, № 13. — P. 3661−80.
- Hajduk, P. J. Puzzling through fragment-based drug design / P. J. Hajduk // Nat. Chem. Biol.2006. — Vol. 2, № 12. — P. 658−9.
- Murray, C. W. Application of fragment screening by X-ray crystallography to beta-secretase / C. W. Murray, O. Callaghan, G. Chessari et al. // J. Med. Chem. — 2007. — Vol. 50, № 6, —P. 1116−23.
- Congreve, M. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase / M. Congreve, D. Aharony, J. Albert et al. // J. Med. Chem. — 2007. — Vol. 50, № 6. — P. 1124−32.
- Nienaber, V. L. Discovering novel ligands for macromolecules using X-ray crystallographic screening / V. L. Nienaber, P. L. Richardson, V. Klighofer et al. // Nat. Biotechnol. — 2000.—Vol. 18, № 10, —P. 1105−8.
- Jhoti, H. Fragment-based screening using X-ray crystallography and NMR spectroscopy / H. Jhoti, A. Cleasby, M. Verdonk et al. // Curr. Opin. Chem. Biol. — 2007. — Vol. 11, № 5.1. P. 485−93.
- Poulsen, S.-A. In Situ Fragment-Based Medicinal Chemistry: Screening by Mass Spectrometry. Fragment-Based Drug Discovery. / S.-A. Poulsen, G. H. Kruppa. Chichester, UK: John Wiley & Sons, Ltd., 2008. P. 159−198. — ISBN 9 780 470 721 551.
- Ciulli, A. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods / A. Ciulli, G. Williams, A. G. Smith et al. // J. Med. Chem. — 2006.
- Vol. 49, № 16. — P. 4992−5000.
- Neumann, T. SPR-based fragment screening: advantages and applications / T. Neumann, H. D. Junker, K. Schmidt et al. // Curr. Top. Med. Chem. — 2007. — Vol. 7, № 16. — P. 1630−42.
- Miura, T. Fragment screening using surface plasmon resonance optical biosensor technology / T. Miura // Yakugaku Zasshi. — 2010. — Vol. 130, № 3. — P. 341−8.
- Kuntz, I. D. The maximal affinity of ligands / I. D. Kuntz, K. Chen, K. A. Sharp etal. // Proc. Natl. Acad. Sci. USA. — 1999. — Vol. 96, № 18. — P. 9997−10 002.
- Bembenek, S. Ligand efficiency and fragment-based drug discovery / S. Bembenek, B. Tounge, and C. Reynolds // Drug Discov. Today. — 2009. — Vol. 14, № 5−6. — P. 278−283.
- Chessari, G. From fragment to clinical candidate—a historical perspective / G. Chessari, A. J. Woodhead // Drug Discov. Today. — 2009. — Vol. 14, № 13−14. — P. 668−75.
- Abad-Zapatero, C. Ligand efficiency indices as guideposts for drug discovery / C. Abad-Zapatero, J. T. Metz // Drug Discov. Today. — 2005. — Vol. 10, № 7. — P. 464−9.
- Hubbard, R. Fragment approaches in structure-based drug discovery / R. Hubbard // Journal of Synchrotron Radiation. — 2008. — Vol. 15, № 3. — P. 227−230.
- Congreve, M. A 'rule of three' for fragment-based lead discovery? / M. Congreve, R. Carr,
- C. Murray et al. // Drug Discov. Today. — 2003. — Vol. 8, № 19. — P. 876−7.
- Schade, M. NMR fragment screening: Advantages and applications / M. Schade // IDrugs.2006. — Vol. 9, № 2. — P. 110−3.
- Hartshorn, M. J. Fragment-based lead discovery using X-ray crystallography / M. J. Hartshorn, C. W. Murray, A. Cleasby et al. // J. Med. Chem. — 2005. — Vol. 48, № 2. — P. 403−13.
- Huber, W. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions / W. Huber // J. Mol. Recognit. — 2005. — Vol. 18, № 4. — P. 273−81.
- Mercier, K. A. Design and characterization of a functional library for NMR screening against novel protein targets / K. A. Mercier, K. Germer, and R. Powers // Comb. Chem. High Throughput Screen. — 2006. — Vol. 9, № 7. — P. 515−34.
- Hajduk, P. J. Integration of NMR and high-throughput screening / P. J. Hajduk, D. J. Burns // Comb. Chem. High Throughput Screen. — 2002. — Vol. 5, № 8. — P. 613−21.
- Bayley, D. Fragment-based drug design: why it’s so important? ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. /
- D. Bayley, S. Boyd. 2009. — Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.iotanharma.com/data2/FBDDOverview.pdf, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- Artis, D. R. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent / D. R. Artis, J. J. Lin, C. Zhang et al. // Proc. Natl. Acad. Sci. USA. — 2009. — Vol. 106, № 1. —P. 262−7.
- Calderwood, S. K. Heat shock proteins in cancer: chaperones of tumorigenesis / S. K. Calderwood, M. A. Khaleque, D. B. Sawyer et al. // Trends Biochem. Sci. — 2006. — Vol. 31, № 3. —P. 164−72.
- Huth, J. R. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies / J. R. Huth, C. Park, A. M. Petros et al. // Chem. Biol. Drug Des. — 2007.—Vol. 70,№ 1. —P. 1−12.
- ACD ChemSketch Freeware ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.acdlabs.com/resources/freeware/chemsketch, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- CORINA ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.molecular-networks.com/products/corina, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- GAUSSIAN ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.gaussian.com, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- Humphrey, W. VMD: visual molecular dynamics / W. Humphrey, A. Dalke, and K. Schulten // J. Mol. Graph. — 1996. — Vol. 14, № 1. — P. 33−8,27−8.
- Schrodinger. The PyMOL Molecular Graphics System, Version 1.3 ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ.
- Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.pymol.org/pvmoL ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- PerlMol Perl Modules for Molecular Chemistry ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. / I. Tubert-Brohman. — Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.perlmol.org, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- Guha, R. The Blue Obelisk-interoperability in chemical informatics / R. Guha, M. T. Howard, G. R. Hutchison et al. // J. Chem. Inf. Model. — 2006. — Vol. 46, № 3. — P. 991−8.
- VitasM Laboratory ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://vitasmlab.com, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- Enamine ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.enamine.net ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ.1. ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- Neria, Π. Simulation of activation free energies in molecular systems / E. Neria, S. Fischer, and M. Karplus // J. Chem. Phys. — 1996. — Vol. 105, № 5. — P. 1902−1921."
- Mehler, E. L. Self-Consistent, Free Energy Based Approximation To Calculate pll Dependent Electrostatic Effects in Proteins / E. L. Mehler // J. Phys. Chem. — 1996. — Vol. 100, № 39. —P. 16 006−16 018.
- Gasteiger, J. Empirical approaches to the calculation of properties, in Chemoinformatics: a textbook. / J. Gasteiger, T. Engel. Darmstadt, Germany: Wiley-VCH, 2003. — 680 p. -ISBN 978−3-527−30 681−7.
- Caliper LifeSciences ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.caliperls.com/products/contract-research/in-vitro/kinases/cdk2cyclina-h.htm, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ. — ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- Reaction Biology Corp. ΠΠ»Π΅ΠΊΡΡΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡΡΡ. Π Π΅ΠΆΠΈΠΌ Π΄ΠΎΡΡΡΠΏΠ°: http://www.reactionbiologv.com/Kinases/Invitrogenl00114/ABLl T315I. pdf, ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠΉ.1. ΠΠ°Π³Π». Ρ ΡΠΊΡΠ°Π½Π°.
- Zarrinkar, P. P. ΠΠ‘220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) / P. P. Zarrinkar, R. N. Gunawardane, M. D. Cramer et al. // Blood. — 2009. — Vol. 114, № 14. — P. 2984−92.
- Fabian, M. A. A small molecule-kinase interaction map for clinical kinase inhibitors / M. A. Fabian, W. H. Biggs, 3rd, D. K. Treiber et al. // Nat. Biotechnol. — 2005. — Vol. 23, № 3.1. P. 329−36.
- Karaman, M. W. A quantitative analysis of kinase inhibitor selectivity / M. W. Karaman, S. Herrgard, D. K. Treiber et al. // Nat. Biotechnol. — 2008. — Vol. 26, № 1. — P. 127−32.
- DesJarlais, R. L. Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease / R. L. DesJarlais, G. L. Seibel, I. D. Kuntz et al. // Proc. Natl. Acad. Sci. USA. — 1990. — Vol. 87, № 17. — P. 6644−8.
- Shoichet, Π. K. Structure-based discovery of inhibitors of thymidylate synthase / Π. K. Shoichet, R. M. Stroud, D. V. Santi et al. // Science. — 1993. — Vol. 259, № 5100. — P.1 861 445−50.
- Gruneberg, S. Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation / S. Gruneberg, M. T. Stubbs, and G. Klebe // J. Med. Chem. — 2002. — Vol. 45, № 17. — P. 3588−602.
- Powers, R. A. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase / R. A. Powers, F. Morandi, and B. K. Shoichet // Structure. — 2002. — Vol. 10, № 7. —P. 1013−23.
- Stahl, M. Detailed analysis of scoring functions for virtual screening / M. Stahl, M. Rarey // J. Med. Chem. — 2001. — Vol. 44, № 7. p. 1035−42.
- Huang, N. Benchmarking Sets for Molecular Docking /N. Huang, B. K. Shoichet, and J. J. Irwin// J. Med. Chem. — 2006. — Vol. 49, № 23. — P. 6789−6801.
- Verdonk, M. L. Virtual screening using protein-ligand docking: avoiding artificial enrichment / M. L. Verdonk, V. Berdini, M. J. Hartshorn et al. // J. Chem. Inf. Comput. Sci. — 2004. — Vol. 44, № 3. — P. 793−806.
- Novikov, F. N. Developing novel approaches to improve binding energy estimation and virtual screening: a PARP case study / F. N. Novikov, V. S. Stroylov, O. V. Stroganov et al. //J. Mol. Model. —2009.—Vol. 15, № 11. — P. 1337−47.
- Xiao, S. H. An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1 / S. H. Xiao, E. Farrelly, J. Anzola et al. //Anal. Biochem. — 2007. — Vol. 367, № 2. — P. 179−89.
- Korkina, L. The chemical defensive system in the pathobiology of idiopathic environment-associated diseases / L. Korkina, M. G. Scordo, I. Deeva et al. // Curr. Drug Metab. — 2009.—Vol. 10,№ 8.— P. 914−31.
- Kohyama, N. Inhibition of arachidonate lipoxygenase activities by 2-(3,4-dihydroxyphenyl)ethanol, a phenolic compound from olives / N. Kohyama, T. Nagata, S.
- Fujimoto et al. // Biosci. Biotechnol. Biochem. — 1997. — Vol. 61, № 2. — P. 347−50.
- Pevarello, P. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding / P. Pevarello, M. G. Brasca, R. Amici et al. // J. Med. Chem. — 2004. — Vol. 47, № 13. —P. 3367−80.
- Congreve, M. S. Detection of ligands from a dynamic combinatorial library by X-ray crystallography / M. S. Congreve, D. J. Davis, L. Devine et al. // Angew. Chem. Int. Ed. Engl. — 2003. — Vol. 42, № 37. — P. 4479−82.
- Aronov, A. M. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors / A. M. Aronov, C. Baker, G. W. Bemis et al. // J. Med. Chem. — 2007. — Vol. 50, № 6. —P. 1280−7.
- Gill, A. L. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation / A. L. Gill, M. Frederickson, A. Cleasby et al. // J. Med. Chem. — 2005. — Vol. 48, № 2. — P. 414−26.
- Howard, S. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity / S. Howard, V. Berdini, J. A. Boulstridge et al. // J. Med. Chem. — 2009. — Vol. 52, № 2. — P. 379−88.
- Hajduk, P. J. Identification of novel inhibitors of urokinase viaNMR-based screening / P. J. Hajduk, S. Boyd, D. Nettesheim et al. // J. Med. Chem. — 2000. — Vol. 43, № 21. — P. 3862−6.
- Frederickson, M. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator / M. Frederickson, O. Callaghan, G. Chessari etal. //J. Med. Chem. — 2008. — Vol. 51, № 2. — P. 183−6.
- Agnelli, G. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement / G. Agnelli, S. Haas, J. S. Ginsberg et al. // J. Thromb. Haemost. — 2007. — Vol. 5, № 4. p. 746−53.
- Pang, Y.-P. Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase / Y.-P. Pang, P. Quiram, T. Jelacic et al. // Journal of Biological Chemistry. — 1996. — Vol. 271, № 39. — P. 23 646−23 649.
- Murray, C. W. Application of Fragment Screening by X-ray Crystallography to p-Secretase / C. W. Murray, O. Callaghan, G. Chessari et al. // J. Med. Chem. — 2007. — Vol. 50, № 6.1. P. 1116−1123.
- Hochgurtel, M. Target-induced formation of neuraminidase inhibitors from in vitro virtual combinatorial libraries / M. Hochgurtel, H. Kroth, D. Piecha et al. // Proc. Natl. Acad. Sci. USA. — 2002. — Vol. 99, № 6. — P. 3382−7.
- Rath, V. L. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site / V. L. Rath, M. Ammirati, D. E. Danley et al. // Chem. Biol. — 2000. — Vol. 7, № 9. — P. 677−82.
- Card, G. L. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design / G. L. Card, L. Blasdel, B. P. England et al. // Nat. Biotechnol.2005. — Vol. 23, № 2. — P. 201−7.
- Burgess, L. E. Potent selective nonpeptidic inhibitors of human lung tryptase / L. E. Burgess, B. J. Newhouse, P. Ibrahim etal. // Proc. Natl. Acad. Sci. USA. — 1999. — Vol. 96, № 15. — P. 8348−52.
- Dymock, B. W. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design / B. W. Dymock, X. Barril, P. A. Brough et al. //
- J. Med. Chem. — 2005. — Vol. 48, № 13. — P. 4212−5.
- Hohwy, M. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design / M. Hohwy, L. Spadola, B. Lundquist et al. // J. Med. Chem. — 2008. — Vol. 51, № 7. —P. 2178−86.
- Liu, T. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities / T. Liu, Y. Lin, X. Wen et al. // Nucleic Acids Res. — 2007. — Vol. 35, β Database issue. — P. D198−201.
- Pevarello, P. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization / P. Pevarello, M. G. Brasca, P. Orsini et al. // J. Med. Chem. — 2005. — Vol. 48, № 8, —P. 2944−56.
- Kim, K. S. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities / K. S. Kim, S. D. Kimball, R. N. Misra et al. // J. Med. Chem. — 2002. — Vol. 45, № 18. — P. 3905−27.
- Thompson, J. E. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor / J. E. Thompson, R. M. Cubbon, R. T. Cummings et al. // Bioorg. Med. Chem. Lett. — 2002. — Vol. 12, № 8. — P. 1219−23.
- Schlapbach, A. Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity / A. Schlapbach, R. Feifel, S. Hawtin et al. // Bioorg. Med. Chem. Lett. — 2008. — Vol. 18, № 23. — P. 6142−6.
- Furet, P. Structure-based design and protein X-ray analysis of a protein kinase inhibitor / P. Furet, T. Meyer, A. Strauss et al. // Bioorg. Med. Chem. Lett. — 2002. — Vol. 12, № 2. — P. 221−4.